Literature DB >> 32642067

Second SVC stent treatment for tumour ingrowth.

Yutaka Takahara1, Yoko Ishige1, Ikuyo Shionoya1, Yuki Fujimoto1, Taku Oikawa1, Shiro Mizuno1.   

Abstract

We herein report a case of lung cancer with recurrent superior vena cava (SVC) syndrome, which was treated with additional stent placement. Our report suggests the possibility that additional SVC stent placement is an option for treatment of tumour ingrowth, even in patients with poor performance status.
© 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.

Entities:  

Keywords:  Additional stent; SVC syndrome; lung cancer; tumour ingrowth

Year:  2020        PMID: 32642067      PMCID: PMC7330812          DOI: 10.1002/rcr2.619

Source DB:  PubMed          Journal:  Respirol Case Rep        ISSN: 2051-3380


Clinical Image

A 78‐year‐old woman had previously received chemoradiotherapy for lung squamous cell carcinoma. She was hospitalized with dyspnoea and oedema of the upper body. Chest computed tomography (CT) (Fig. 1) revealed worsening of the primary lesion causing superior vena cava (SVC) compression. Therefore, an SVC stent was placed. She had a performance status (PS) of 1. However, because of disease progression, her PS worsened from 1 to 3. Chest CT (Fig. 2) revealed the stent to be obstructed by tumour ingrowth. We decided to perform an additional SVC stenting. The guide wire was introduced via the right internal jugular vein. The wire was grasped with a snare on the opposite side from the right femoral vein approach. An additional SVC stent was placed, with its lower tip proximal to the right atrium (Fig. 3). After stent placement, her symptoms (dyspnoea and oedema) improved immediately with no complications. At one‐month follow‐up, she remained asymptomatic. Endovascular stents have been applied to treat SVC syndrome (SVCS). However, their effectiveness for SVCS with recurrent disease is unclear [1]. Our report suggests the possibility that an additional SVC stent is an option for treatment of tumour ingrowth, even in patients with poor PS.
Figure 1

Contrast‐enhanced computed tomography (CT) images of the thorax in the axial (A) and coronal (B) planes. Chest CT showed a mediastinal mass and severe stenosis of the superior vena cava. The tumour invaded the mediastinum.

Figure 2

Contrast‐enhanced computed tomography (CT) images of the thorax in the axial (A) and coronal (B) planes. Chest CT showed proximal obstruction of the initial superior vena cava (SVC) stent by tumour ingrowth (arrows).

Figure 3

An angiograph (A) and computed tomography (CT) scan (B) of the post‐stenting superior vena cava (SVC). (A) An additional SVC stent was placed and post‐stenting venogram showed flow improvement in the SVC. (B) The distal end of the additional stent was located just proximal to the right atrium.

Contrast‐enhanced computed tomography (CT) images of the thorax in the axial (A) and coronal (B) planes. Chest CT showed a mediastinal mass and severe stenosis of the superior vena cava. The tumour invaded the mediastinum. Contrast‐enhanced computed tomography (CT) images of the thorax in the axial (A) and coronal (B) planes. Chest CT showed proximal obstruction of the initial superior vena cava (SVC) stent by tumour ingrowth (arrows). An angiograph (A) and computed tomography (CT) scan (B) of the post‐stenting superior vena cava (SVC). (A) An additional SVC stent was placed and post‐stenting venogram showed flow improvement in the SVC. (B) The distal end of the additional stent was located just proximal to the right atrium.

Disclosure Statement

Appropriate written informed consent was obtained for publication of this case report and accompanying images.
  1 in total

1.  Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study.

Authors:  Haitao Liu; Yahua Li; Yang Wang; Lei Yan; Pengli Zhou; Xinwei Han
Journal:  J Cardiothorac Surg       Date:  2021-03-20       Impact factor: 1.637

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.